lymphoma
Novartis Nabs European Approval for Kymriah in Follicular Lymphoma
The European Commission approved the autologous CAR T-cell therapy for relapsed or refractory follicular lymphoma patients after two or more prior treatments.
Novartis Q1 Revenues Grow 1 Percent Amid Organizational Restructuring, Shifting Growth Drivers
The firm highlighted revenue growth for its CDK4/6 inhibitor Kisqali and strong sales potential for recent launches Pluvicto and Scemblix, but not for its cell therapy Kymriah.
Mustang Bio Expanding Phase I/II Trial of Anti-CD20 CAR T-Cell Therapy
After seeing strong responses to MB-106 in patients at Fred Hutchinson Cancer Center, the firm will begin enrolling patients at other institutions.
FDA Lifts Partial Clinical Holds for Some Gilead Trials
Gilead's Phase III ENHANCE trials of magrolimab combinations are clear to move forward, while earlier stage trials in blood cancers remain in limbo.Â
AACR Data Show Donor NK Cells Plus Bispecific Antibody Could Benefit CD30-Positive Lymphoma Patients
Premium
The off-the-shelf approach led to encouraging responses in a Phase I study and could be easier to manufacture and less costly than autologous CAR T-cell therapy.